<DOC>
	<DOCNO>NCT01659970</DOCNO>
	<brief_summary>This observational study evaluate efficacy safety Tarceva ( erlotinib ) second line patient locally advance metastatic squamous non-small cell lung cancer ( NSCLC ) failure first line platinum-based chemotherapy . Eligible patient follow 12 month .</brief_summary>
	<brief_title>PEPITA Study : An Observational Study Tarceva ( Erlotinib ) Second Line Patients With Locally Advanced Metastatic Squamous Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Histologically cytologically confirm advanced ( Stage IIIB ) metastatic ( Stage IV ) squamous nonsmall cell lung cancer failure firstline platinumbased chemotherapy Patients treat physician decide initiate treatment Tarceva Mixed nonsmall cell smallcell lung carcinoma mixed squamous cell carcinoma predominant adenocarcinoma component Current participation clinical trial evaluate anticancer treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>